Biogen Idec Agrees To Buy Syntonix
This article was originally published in The Pink Sheet Daily
Biogen gains preclinical hemophilia B agent and novel delivery technology that could allow less frequent dosing.
You may also be interested in...
The hemophilia market could be about to undergo a wave of innovation not seen since the introduction of recombinant factor 20 years ago in response to a crisis in contaminated plasma products. Over the next three years, long-acting factor products may have an even more transformative effect on the market, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market. But will the improvements be enough to sway providers and payors?
Biogen Idec reported steady progress in the clinic for four late-stage programs, including hemophilia. Recent bumps include a three-month delay for the MS product BG-12, but nothing that would derail its Phase III pipeline.
The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.